← Product Code [GCJ](/productcode/GCJ) · K112349 # VERSAPORT V2 BLADELESS OPTIICAL TROCAR AND/OR VERSAPORT BLADELESS OPTICAL TROCAR (K112349) _Covidien, Formerly US Surgical A Divison of Tyco H · GCJ · Sep 1, 2011 · Gastroenterology, Urology · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K112349 ## Device Facts - **Applicant:** Covidien, Formerly US Surgical A Divison of Tyco H - **Product Code:** [GCJ](/productcode/GCJ.md) - **Decision Date:** Sep 1, 2011 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 876.1500 - **Device Class:** Class 2 - **Review Panel:** Gastroenterology, Urology ## Indications for Use The Versaport™ Bladeless Optical Trocar is intended for use in a variety of gynecologic, general, thoracic and urologic endoscopic procedures to create and maintain a port of entry. The trocar may be used with or without visualization for primary and secondary insertions. ## Device Story Versaport™ V2 Bladeless Optical Trocar facilitates endoscopic access to body cavities. Device consists of cannula, bladeless obturator with transparent optical window, and housing with scope retention mechanism. Surgeon inserts 0° laparoscope through obturator to visualize tissue layers during entry. Internal seals maintain pneumoperitoneum; luer lock allows insufflation/desufflation. Used in OR by surgeons for primary/secondary port creation. Provides visual confirmation of tissue penetration, reducing risk of blind entry complications. ## Clinical Evidence Bench and in-vivo testing performed. Metrics included leak resistance, penetration/fixation forces, insertion/removal forces, snap feature retention, and scope retention. In-vivo testing validated visualization of tissue layers and multiple penetration performance. No clinical trial data required for this device type. ## Technological Characteristics Cannula with transparent fixation; bladeless obturator with optical window; scope retention mechanism; external interlocking snaps. Materials tested per ISO 10993-1. Manual mechanical operation; no energy source or software. ## Regulatory Identification An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations. ## Special Controls *Classification* —(1)*Class II (special controls).* The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9. In combination with the general controls of the FD&C Act, the integrated operating table-electromechanical surgical system is subject to the following special controls: 1. (1) Premarket clinical performance testing, or a combination of premarket clinical performance testing and postmarket surveillance (in accordance with special control (2)), must include the following: 1. (i) Objective performance measures (e.g., rate and number of conversions to other surgical modalities, rate of device related adverse events (including tissue injury, hematoma, and increased blood loss), and their severity, cause, and outcomes) must be reported with relevant descriptive comparator performance measures. 2. (ii) The data must demonstrate the performance of the device for providing accurate and precise control of attached surgical instruments in range of clinical conditions relevant to the device's intended use. 3. (iii) The test dataset must include data collected from a patient population representative of the intended patient population under anticipated conditions of use. 2. (2) Data obtained from postmarket surveillance must demonstrate, in consideration of the premarket data obtained in accordance with special control (1), that the device performs in accordance with special control (1), unless FDA determines, based on the totality of the premarket data, that data from postmarket surveillance is not required to demonstrate that the device performs as intended. Such postmarket surveillance must be conducted per a protocol determined appropriate by FDA to demonstrate that the device performs as intended (in consideration of the premarket data obtained in accordance with special control (1)), and must include initiation, enrollment, and reporting requirements to ensure timely periodic updates to FDA on post-market surveillance progress and outcomes. 3. (3) Animal performance testing must evaluate the extent of port site trauma due to repositioning of table during surgical procedures when utilizing robotic minimally invasive and laparoscopic approaches 4. (4) The device manufacturer must develop, and update as necessary, a device-specific use training program that ensures proper device setup/use/shutdown, accurate control of instruments to perform the intended surgical procedures, troubleshooting and handling during unexpected events or emergencies, and safe practices to mitigate use error. 5. (5) The device manufacturer may only distribute the device to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program. (6) Human factors assessment must demonstrate that the user can correctly use the device system across all intended use environments with the provided instructions and training materials, including patient access during normal operating conditions and emergency situations, and effects arising from the integrated nature of the operating table and robotic surgical arms. (7) Labeling must include: (i) A detailed summary of clinical performance testing conducted with the device, including study population, results, adverse events, and comparisons to any comparator groups identified; (ii) A statement in the labeling that the safety and effectiveness for the representative specific procedures was based on evaluation of the device as a surgical tool and did not include evaluation of outcomes related to the treatment of the patient's underlying disease or condition, unless FDA determines that it can be removed or modified based on clinical performance data submitted to FDA; (iii) Identification of compatible devices; (iv) The list of surgical procedures for which the device has been determined to be safe with clinical justification; (v) Reprocessing instructions for reusable components; (vi) A shelf life for any sterile components; (vii) A description of the device-specific use training program; (viii) A statement that the device is only for distribution to facilities that implement and maintain the device-specific use training program and ensure that users of the device have completed the device-specific use training program; and (ix) A summary of any completed postmarket surveillance data collected as required by special control (2), including updated labeling to accurately reflect outcomes observed in postmarket surveillance. (8) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use and must include: (i) Device motion accuracy and repeatability; (ii) System testing; (iii) Instrument reliability; (iv) Crosstalk; (v) Table motion control; (vi) Thermal effects on tissue; (vii) User-device interface performance; (viii) Workspace access testing; and (ix) Performance testing with compatible devices. (9) Software verification, validation, and hazard analysis must be performed. (10) Electromagnetic compatibility and electrical, thermal, and mechanical safety testing must be performed. (11) Performance data must demonstrate the sterility of all patient-contacting device components. (12) Performance data must support the shelf life of the device components provided sterile by demonstrating continued sterility and package integrity over the labeled shelf life. (13) Performance data must validate the reprocessing instructions for the reusable components of the device. (14) Performance data must demonstrate that all patient-contacting components of the device are biocompatible. (15) Performance data must demonstrate that all patient-contacting components of the device are non-pyrogenic. (16) The device manufacturer must submit a report to the FDA annually on the anniversary of initial marketing authorization for the device, until such time as FDA may terminate such reporting, which comprises the following information: (i) Cumulative summary, by year, of complaints and adverse events since date of initial marketing authorization; and (ii) Identification and rationale for changes made to the device, labeling, or device specific use training program, which did not require submission of a premarket notification during the reporting period. ## Predicate Devices - Versaport™ Bladeless Low ProfileTrocar ([K100548](/device/K100548.md)) - Endopath® Xcel™ Trocar ([K011257](/device/K011257.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ .112349 Versaport™ V2 Bladeless Optical Trocar System SEP - 1 2011 ## 510(k) Summary of Safety and Effectiveness | SUBMITTER: | Covidien
60 Middletown Avenue
North Haven, CT 06473 USA | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | CONTACT PERSON: | Angela Van Arsdale
Product Specialist, Regulatory Affairs | | DATE PREPARED: | August 10, 2011 | | TRADE/PROPRIETARY NAME: | Versaport™ V2 Bladeless Optical Trocar or Versaport™ Bladeless
Optical | | COMMON/USUAL NAME: | Surgical Trocar | | CLASSIFICATION NAME: | Endoscope and Accessories | | PREDICATE DEVICE(S): | Versaport™ Bladeless Low ProfileTrocar [K100548] | | | Endopath® Xcel™ Trocar [K011257] | | DEVICE DESCRIPTION: | The Versaport™ V2 bladeless optical trocar with a low profile design
and transparent fixation cannula is available in 5 mm standard
(100mm), 5 mm short (70mm) and 5mm long (150mm) cannula
lengths. The Versaport™ V2 bladeless optical 5mm trocar with
transparent fixation cannula and obturator allows optical entry for
visualization of tissue layers during insertion. The obturator housing
contains a scope retention mechanism. The trocar housing contains
internal seals to prevent loss of pneumoperitoneum when instruments
are inserted into a port or withdrawn completely from a port. The 5 mm
Versaport™ seal system accommodates 5mm instruments
respectively. There is a luer lock with cap for insufflation and rapid
desufflation. | | INTENDED USE: | The Versaport™ Bladeless Optical Trocar is intended for use in a
variety of gynecologic, general, thoracic and urologic endoscopic
procedures to create and maintain-a-port-of entry. The trocar may be
used with or without visualization for primary and secondary insertions. | | TECHNICAL
CHARACTERISTICS: | The subject device (Versaport™ V2 Bladeless Optical Trocar) has
similar design, lengths, and optical features as the predicate devices.
The design modifications includes a cannula material change, a
bladeless obturator with a transparent optical window at the distal end,
an obturator housing scope retention mechanism and external
interlocking snaps. The scope retention mechanism is located within
the obturator housing allowing for secured insertion and retention of an
appropriately sized 0° laparoscope for visualization of tissue layers
during insertion into the body cavity. The external interlocking snaps
secure the obturator to the cannula. The Versaport™ Bladeless V2
Optical trocar is equivalent to the predicate devices in terms of its
intended use and fundamental technology. | | MATERIALS: | All components of the Versaport™ Bladeless Optical Trocar are
comprised of materials which were tested in accordance with ISO
10993-1 | Special 510(k)Premarket Notification August 2011 Page 22 ™Trademark P 1/2 {1}------------------------------------------------ ### Versaport™ V2 Bladeless Optical Trocar System #### PERFORMANCE DATA: In-vitro and in-vivo tests were performed to verify that the performance of the Versaport™ V2 Bladeless Optical 5mm trocar is substantially equivalent to the predicate device, Endopath® Xcel trocar [K011257], To validate that the subject device performs as intended to facilitate endoscopic access into the body cavity, the following describes the testing performed: . . . . . - In Vitro Leak Resistance . - In Vitro and In Vivo Penetration and Fixation Forces . - In Vitro and In Vivo Fixation Force - In Vitro and In Vivo Insertion and Removal Forces . - In Vitro Snap Feature Retention Force ● - In Vitro One-Handed Use ● - In Vitro Scope Insertion and Retention Forces - In Vivo Multiple Penetration Forces - In Vivo Visualization of Tissue Layers \$\frac{P4}{2}\$ {2}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with its wings spread, symbolizing protection and care. The eagle is positioned within a circular border that contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a sans-serif font. The text is arranged around the circumference of the circle, framing the eagle symbol. Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Covidien % Ms. Angela Van Arsdale Regulatory Affairs Product Specialist 60 Middletown Avenue North Haven, Connecticut 06473 SEP - 1 2011 Re: K112349 Trade/Device Name: Versaport™ V2 Bladeless Optical Trocar Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and accessories Regulatory Class: II Product Code: GCJ Dated: August 15, 2011 Received: August 16, 2011 Dear Ms. Arsdale: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilsting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 {3}------------------------------------------------ Page 2 - Ms. Angela Van Arsdale CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, For Peter m.ait DEN CLP D/N Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use -11234 510(k) Number (if known): Device Name: Versaport™ V2 Bladeless Optical Trocar Indications for Use: The Versaport™ Bladeless Optical Trocar is intended for use in a variety of gynecologic, general, thoracic and urologic endoscopic procedures to create and maintain a port of entry. The trocar may be used with or without visualization for primary and secondary insertions. Prescription Use X (21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Neil R.P. Ogden for MSR (Division Sign-Off Division of Surgical, Orthopedic, and Restorative Devices 510(k) Number K112349 Special 510(k)Premarket Notification August 2011 Page 20 ™ Trademark --- **Source:** [https://fda.innolitics.com/device/K112349](https://fda.innolitics.com/device/K112349) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com